A senior leader at Kineticos, while serving as an executive at a top 5 pharmaceutical company, was tasked with evaluating the expansion into the biologic therapeutic area for a diabetes treatment. The company’s objective was to target GLP-1 with an antibody or fusion protein as an agonist, which was a first-in-class agent at the time. To justify the investment required to launch such a program, the company was in need of a comprehensive commercial analysis for the breakthrough therapy expected to impact practice and treatment protocols
Through primary and secondary market research and the use of proven commercial models, the team conducted a comprehensive market assessment that included the below components, which were weaved into a scalable commercial and clinical development plan.
- Disease overview
- Treatment evaluation of current and future therapies
- Target product profile with an attribute sensitivity assessment
- Asset valuation
- Revenue assessment
- Go / No-Go Decision Tree Analysis
Using a validated financial model, the total asset value was identified and its allure played a significant role in advising the executive team to move forward with the investment. Having a fact-based commercial analysis provided the company with enough data to confidently approve the investment decision and initiate the program.